IL166010A0 - Piperidine derivatives and their use as selective inhibitors of MIP-1alpha binding to its receptor CCR1 - Google Patents
Piperidine derivatives and their use as selective inhibitors of MIP-1alpha binding to its receptor CCR1Info
- Publication number
- IL166010A0 IL166010A0 IL16601004A IL16601004A IL166010A0 IL 166010 A0 IL166010 A0 IL 166010A0 IL 16601004 A IL16601004 A IL 16601004A IL 16601004 A IL16601004 A IL 16601004A IL 166010 A0 IL166010 A0 IL 166010A0
- Authority
- IL
- Israel
- Prior art keywords
- mip
- selective inhibitors
- piperidine derivatives
- receptor ccr1
- 1alpha
- Prior art date
Links
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 title 1
- 101710149814 C-C chemokine receptor type 1 Proteins 0.000 title 1
- 108700012434 CCL3 Proteins 0.000 title 1
- 102000000013 Chemokine CCL3 Human genes 0.000 title 1
- 229940124639 Selective inhibitor Drugs 0.000 title 1
- 150000003053 piperidines Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39710802P | 2002-07-18 | 2002-07-18 | |
| PCT/IB2003/002876 WO2004009550A1 (en) | 2002-07-18 | 2003-07-07 | Piperidine derivatives and their use as selective inhibitors of mip-1alpha binding to its receptor ccr1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL166010A0 true IL166010A0 (en) | 2006-01-15 |
Family
ID=30770997
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL16601004A IL166010A0 (en) | 2002-07-18 | 2004-12-27 | Piperidine derivatives and their use as selective inhibitors of MIP-1alpha binding to its receptor CCR1 |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20040063759A1 (de) |
| EP (1) | EP1534677A1 (de) |
| JP (1) | JP2005537279A (de) |
| KR (1) | KR20050021497A (de) |
| CN (1) | CN1668592A (de) |
| AP (1) | AP2005003200A0 (de) |
| AR (1) | AR040583A1 (de) |
| AU (1) | AU2003242941A1 (de) |
| BR (1) | BR0312946A (de) |
| CA (1) | CA2492651A1 (de) |
| EC (1) | ECSP055547A (de) |
| HN (1) | HN2003000222A (de) |
| IL (1) | IL166010A0 (de) |
| IS (1) | IS7614A (de) |
| MA (1) | MA27326A1 (de) |
| MX (1) | MXPA05000380A (de) |
| OA (1) | OA12885A (de) |
| PA (1) | PA8575901A1 (de) |
| PE (1) | PE20040666A1 (de) |
| TN (1) | TNSN05014A1 (de) |
| TW (1) | TW200402416A (de) |
| UY (1) | UY27897A1 (de) |
| WO (1) | WO2004009550A1 (de) |
| ZA (1) | ZA200500067B (de) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7399790B2 (en) | 2001-02-28 | 2008-07-15 | Konowalchuk Thomas W | Virucidal compositions |
| US7493363B2 (en) | 2001-09-19 | 2009-02-17 | Microsoft Corporation | Peer-to-peer group management and method for maintaining peer-to-peer graphs |
| US7589199B2 (en) | 2002-06-12 | 2009-09-15 | Chemocentryx, Inc. | Substituted piperazines |
| DK1531822T3 (da) | 2002-06-12 | 2009-12-07 | Chemocentryx Inc | 1-aryl-4-substituerede piperazin derivater til anvendelse som CCR1 antagonister til behandlingen af inflammation og immunforstyrrelser |
| US7842693B2 (en) | 2002-06-12 | 2010-11-30 | Chemocentryx, Inc. | Substituted piperazines |
| WO2004009588A1 (en) * | 2002-07-18 | 2004-01-29 | Pfizer Products Inc. | Bicyclic piperidine derivatives as antagonists of the ccr1 chemokine receptor |
| US8261062B2 (en) | 2003-03-27 | 2012-09-04 | Microsoft Corporation | Non-cryptographic addressing |
| US7288563B2 (en) | 2004-02-19 | 2007-10-30 | Bristol-Myers Squibb Company | Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity |
| US7230022B2 (en) | 2004-02-19 | 2007-06-12 | Bristol-Myers Squibb Company | Substituted fused bicyclic amines as modulators of chemokine receptor activity |
| US7381738B2 (en) | 2004-02-19 | 2008-06-03 | Bristol-Myers Squibb Company | Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity |
| US7479496B2 (en) | 2004-02-19 | 2009-01-20 | Bristol-Myers Squibb Company | Substituted spiro azabicyclics as modulators of chemokine receptor activity |
| AU2005219438B2 (en) | 2004-03-03 | 2011-02-17 | Chemocentryx, Inc. | Bicyclic and bridged nitrogen heterocycles |
| US7435831B2 (en) | 2004-03-03 | 2008-10-14 | Chemocentryx, Inc. | Bicyclic and bridged nitrogen heterocycles |
| US7929689B2 (en) | 2004-06-30 | 2011-04-19 | Microsoft Corporation | Call signs |
| US20060167044A1 (en) * | 2004-12-20 | 2006-07-27 | Arnaiz Damian O | Piperidine derivatives and their use as anti-inflammatory agents |
| US7620902B2 (en) | 2005-04-20 | 2009-11-17 | Microsoft Corporation | Collaboration spaces |
| US7617281B2 (en) | 2005-04-25 | 2009-11-10 | Microsoft Corporation | System and method for collaboration with serverless presence |
| US7660851B2 (en) | 2005-07-06 | 2010-02-09 | Microsoft Corporation | Meetings near me |
| JO2747B1 (en) | 2005-07-26 | 2014-03-15 | جلاكسو جروب ليمتد | Vehicles |
| WO2007073432A2 (en) | 2005-10-11 | 2007-06-28 | Chemocentryx, Inc. | Piperidine derivatives and methods of use |
| US8086842B2 (en) | 2006-04-21 | 2011-12-27 | Microsoft Corporation | Peer-to-peer contact exchange |
| US8069208B2 (en) | 2006-04-21 | 2011-11-29 | Microsoft Corporation | Peer-to-peer buddy request and response |
| EP2202223B1 (de) * | 2007-10-18 | 2017-01-25 | Takeda Pharmaceutical Company Limited | Heterocyclische verbindung als blut-rbp4 senkende agent |
| WO2010077915A1 (en) * | 2008-12-17 | 2010-07-08 | Forest Laboratories Holdings Limited | Novel compounds useful as cc chemokine receptor ligands |
| CN105829296A (zh) | 2013-12-18 | 2016-08-03 | 巴斯夫欧洲公司 | 带有亚胺衍生的取代基的唑类化合物 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE640616A (de) * | 1962-12-19 | |||
| US3492397A (en) * | 1967-04-07 | 1970-01-27 | Warner Lambert Pharmaceutical | Sustained release dosage in the pellet form and process thereof |
| US4060598A (en) * | 1967-06-28 | 1977-11-29 | Boehringer Mannheim G.M.B.H. | Tablets coated with aqueous resin dispersions |
| US3538214A (en) * | 1969-04-22 | 1970-11-03 | Merck & Co Inc | Controlled release medicinal tablets |
| US4173626A (en) * | 1978-12-11 | 1979-11-06 | Merck & Co., Inc. | Sustained release indomethacin |
| WO1997024325A1 (en) * | 1995-12-28 | 1997-07-10 | Takeda Chemical Industries, Ltd. | DIPHENYLMETHANE DERIVATIVES AS MIP-1α/RANTES RECEPTOR ANTAGONISTS |
| ATE308985T1 (de) * | 1999-05-18 | 2005-11-15 | Teijin Ltd | Heilmittel und vorbeugung für mit chemokinen verbundenen erkrankungen |
| AR028947A1 (es) * | 2000-06-20 | 2003-05-28 | Astrazeneca Ab | Compuestos novedosos |
| KR100890676B1 (ko) * | 2001-07-24 | 2009-03-26 | 리히데 게데온 베기에스제티 기아르 알티 | 신규한 카르복시산 아미드 화합물 |
-
2003
- 2003-06-17 PA PA20038575901A patent/PA8575901A1/es unknown
- 2003-07-07 JP JP2004522601A patent/JP2005537279A/ja active Pending
- 2003-07-07 OA OA1200500010A patent/OA12885A/en unknown
- 2003-07-07 AP AP2005003200A patent/AP2005003200A0/xx unknown
- 2003-07-07 WO PCT/IB2003/002876 patent/WO2004009550A1/en not_active Ceased
- 2003-07-07 CA CA002492651A patent/CA2492651A1/en not_active Abandoned
- 2003-07-07 AU AU2003242941A patent/AU2003242941A1/en not_active Abandoned
- 2003-07-07 CN CNA038170922A patent/CN1668592A/zh active Pending
- 2003-07-07 EP EP03765230A patent/EP1534677A1/de not_active Withdrawn
- 2003-07-07 KR KR10-2005-7000849A patent/KR20050021497A/ko not_active Withdrawn
- 2003-07-07 BR BR0312946-2A patent/BR0312946A/pt not_active Application Discontinuation
- 2003-07-07 MX MXPA05000380A patent/MXPA05000380A/es unknown
- 2003-07-08 US US10/616,844 patent/US20040063759A1/en not_active Abandoned
- 2003-07-15 PE PE2003000705A patent/PE20040666A1/es not_active Application Discontinuation
- 2003-07-16 UY UY27897A patent/UY27897A1/es not_active Application Discontinuation
- 2003-07-16 AR AR20030102555A patent/AR040583A1/es unknown
- 2003-07-17 TW TW092119550A patent/TW200402416A/zh unknown
- 2003-07-17 HN HN2003000222A patent/HN2003000222A/es unknown
-
2004
- 2004-12-23 IS IS7614A patent/IS7614A/is unknown
- 2004-12-27 IL IL16601004A patent/IL166010A0/xx unknown
-
2005
- 2005-01-04 ZA ZA200500067A patent/ZA200500067B/en unknown
- 2005-01-18 TN TNP2005000014A patent/TNSN05014A1/fr unknown
- 2005-01-18 MA MA28049A patent/MA27326A1/fr unknown
- 2005-01-18 EC EC2005005547A patent/ECSP055547A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TNSN05014A1 (fr) | 2007-05-14 |
| CA2492651A1 (en) | 2004-01-29 |
| MA27326A1 (fr) | 2005-05-02 |
| ZA200500067B (en) | 2005-11-02 |
| JP2005537279A (ja) | 2005-12-08 |
| BR0312946A (pt) | 2005-07-12 |
| HN2003000222A (es) | 2004-11-23 |
| MXPA05000380A (es) | 2005-03-31 |
| AR040583A1 (es) | 2005-04-13 |
| UY27897A1 (es) | 2004-02-27 |
| OA12885A (en) | 2006-09-15 |
| IS7614A (is) | 2004-12-23 |
| CN1668592A (zh) | 2005-09-14 |
| AU2003242941A1 (en) | 2004-02-09 |
| ECSP055547A (es) | 2005-03-10 |
| EP1534677A1 (de) | 2005-06-01 |
| KR20050021497A (ko) | 2005-03-07 |
| WO2004009550A1 (en) | 2004-01-29 |
| AP2005003200A0 (en) | 2005-03-31 |
| TW200402416A (en) | 2004-02-16 |
| US20040063759A1 (en) | 2004-04-01 |
| PE20040666A1 (es) | 2004-09-25 |
| PA8575901A1 (es) | 2004-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP2005003200A0 (en) | Piperdine derivatives and their use as selective inhibitors of MIP-1alpha binding to its receptor CCR1. | |
| AU2003298514A8 (en) | Methods and compositions using cholinesterase inhibitors | |
| IL173398A0 (en) | Pyridyl derivatives and their use as therapeutic agents | |
| IL182527A0 (en) | Compounds and compositions as inhibitors of cannabinoid receptor 1 activity | |
| EP1656378A4 (de) | Verbindungen und zusammensetzungen als inhibitoren von rezeptor-tyrosinkinase-aktivität | |
| PL375877A1 (en) | Hydantoine derivatives and their use as tace inhibitors | |
| AU2003302919A1 (en) | Pyridine derivatives as jnk inhibitors and their use | |
| IL208249A0 (en) | Spirocyclic heterocyclic derivatives and methods of their use | |
| IL177650A0 (en) | Isoquinoline derivatives and methods of use thereof | |
| AU2003232848A8 (en) | Phenylaminopyrimidines and their use as rho-kinase inhibitors | |
| IL174334A0 (en) | Use of chk1 inhibitors to control cell proliferation | |
| IL180600A0 (en) | Compositions and methods of use for treatment of mammalian diseases | |
| EP1703907A4 (de) | Zusammensetzungen und verfahren zur behandlung von rezidivierenden krankheiten | |
| AU2003215756A8 (en) | Benzimidazoles and their use as mitogen-activated- and rho-kinase inhibitors | |
| EP1638565A4 (de) | Substituierte piperidin-verbindungen und anwendungsverfahren dafür | |
| AU2003269421A8 (en) | Hiv-integrase inhibitors, pharmaceutical compositions, and methods for their use | |
| IL174497A0 (en) | Pyridine derivatives and use thereof as urotensin ii antagonists | |
| IL175179A0 (en) | Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors | |
| AP2006003863A0 (en) | Use of imatinib to treat liver disorders and viralinfections | |
| IL176772A0 (en) | Acylaminothiazole derivatives and use thereof as beta-amyloid inhibitors | |
| PL380189A3 (pl) | Azolidynokarbonitryle i ich zastosowanie jako inhibitory DPP-IV | |
| IL179038A0 (en) | Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases | |
| AU2003289329A1 (en) | Antagonist and agonist binding to strong binding site of chemokine receptor | |
| AU2003231019A8 (en) | Pharmaceutical compositions containing alpha3beta4 nicotinic receptor antagonists and methods of their use | |
| AU2003263988A8 (en) | Methods and compositions to treat conditions associated with neovascularization |